Phanes Therapeutics’ PT217 receives FDA orphan drug designation for neuroendocrine carcinoma

Phanes Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing oncology treatments, has achieved a significant milestone with the granting of Orphan Drug Designation (ODD) ... Read More